PUBLISHER: DelveInsight | PRODUCT CODE: 1125982
PUBLISHER: DelveInsight | PRODUCT CODE: 1125982
"ION363, Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about ION363 for Amyotrophic Lateral Sclerosis in the 7MM. A detailed picture of the ION363 for Amyotrophic Lateral Sclerosis in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019-2032 is provided in this report along with a detailed description of the ION363 for Amyotrophic Lateral Sclerosis. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the ION363 market forecast, analysis for Amyotrophic Lateral Sclerosis in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Amyotrophic Lateral Sclerosis.
ION363 is an investigational antisense medicine designed to reduce the production of the Fused in Sarcoma (FUS) protein. ION363 is also known as Jacifusen (not an official USAN name) in honor of Jaci Hermstad, the first patient treated with the drug under an expanded access program. It is in development for patients with a rare genetic form of ALS caused by mutations in the FUS gene. Mutant FUS causes motor neuron degeneration through a toxic gain of function mechanism. In patients, mutant FUS protein aggregates in motor neurons. Antisense-mediated reduction of mutant FUS protein in a FUS-ALS mouse model prevents motor neuron loss. It is hypothesized that reduction of FUS protein will reverse or prevent disease progression in FUS-ALS patients. By targeting the root cause of FUS-ALS, ION363 can potentially reduce or prevent disease progression in FUS-ALS patients. The company is currently conducting a Phase III trial of the drug for ALS patients with fused in sarcoma mutations (FUS-ALS), and data from this trial is expected in 2025.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
ION363 Analytical Perspective by DelveInsight
This report provides a detailed market assessment of ION363 in Amyotrophic lateral sclerosis in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2025 to 2032.
The report provides the clinical trials information of ION363 in Amyotrophic Lateral Sclerosis covering trial interventions, trial conditions, trial status, start and completion dates.
Key Questions